skip to Main Content

No Clinical Benefit Adding Pegilodecakin to FOLFOX for Pancreatic Cancer

No Clinical Benefit Adding Pegilodecakin to FOLFOX for Pancreatic Cancer
[subhed]Joel Randolph Hecht, MD, David Geffen School of Medicine, University of California Los Angeles, shares findings from the SEQUOIA clinical trial of GEM-refractory pancreatic adenocarcinoma, an overview of recent studies and therapy options for metastatic pancreatic cancer, and what he believes may be the way forward to improve treatment outcomes in this patient population. [/subhead]

The SEQUOIA trial looks at a novel immunotherapy agent which is called pegilodecakin or pegylated IL‑10. IL‑10 has multiple different effects including immunosuppression. It also has effects particularly on T‑cells where it can, in studies both in vivo and early studies in man where it appears they can increase T‑cell clonality and diversity. Listen here . . . 


Back To Top